⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADIL News
Adial Pharmaceuticals, Inc
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
globenewswire.com
ADIL
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ADIL
Form 8-K
sec.gov
ADIL
Form 8-K
sec.gov
ADIL
Alcohol Use Disorder Pipeline Insight, 2026 Examines 25+ Companies and 25+ Emerging Therapies
globenewswire.com
ADIL
BCO